Let me rephrase: In the US Stribild market is #1 in the first-line setting and #1 in new switches in the second-line setting. It's not yet #1 in total sales because there are many patients who are currently stable on other regimens.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”